SML3313
PF-07321332
≥95% (HPLC)
Synonym(s):
Nirmatrelvir, (1R,2S,5S)-N-[(1S)-1-Cyano-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]-3-[(2S)-3,3-dimethyl-1-oxo-2-[(2,2,2-trifluoroacetyl)amino]butyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C23H32F3N5O4
CAS Number:
Molecular Weight:
499.53
UNSPSC Code:
12352200
Quality Level
Assay
≥95% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C(N[C@H](C#N)C[C@@]1(CCNC1=O)[H])[C@H]2N(C[C@]3([C@@]2(C3(C)C)[H])[H])C([C@@H](NC(C(F)(F)F)=O)C(C)(C)C)=O
Biochem/physiol Actions
Nirmatrelvir is a high efficacy oral antiviral that is active against COVID-19 variants, including omicron. PF-07321332 covalently and reversibly binds to the cysteine 145 residue of the viral 3CLpro (SARS-CoV-2 main protease) catalytic domain to inhibit the SARS-CoV-2 replication cycle ( IC50 ~ 4 nM). Nirmatrelvir poorly affects cathepsin-K (IC50 = 231 nM) with no inhibition towards caspases.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Dafydd R Owen et al.
Science (New York, N.Y.), 374(6575), 1586-1593 (2021-11-03)
The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here
Samantha E Greasley et al.
The Journal of biological chemistry, 298(6), 101972-101972 (2022-04-25)
The COVID-19 pandemic continues to be a public health threat with emerging variants of SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2 and the active protease inhibitor in PAXLOVID (nirmatrelvir tablets and ritonavir
Laura Vangeel et al.
Antiviral research, 198, 105252-105252 (2022-01-28)
We assessed the in vitro antiviral activity of remdesivir and its parent nucleoside GS-441524, molnupiravir and its parent nucleoside EIDD-1931 and the viral protease inhibitor nirmatrelvir against the ancestral SARS-CoV2 strain and the five variants of concern including Omicron. VeroE6-GFP
Raymond K Hau et al.
Clinical and translational science, 15(7), 1599-1605 (2022-05-05)
The ongoing pandemic of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) and subsequently, coronavirus disease 2019 (COVID-19), has led to the deaths of over 6.1 million people and sparked a greater interest in virology to expedite the development process for antivirals. The
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service